Clinical Trials Directory

Trials / Completed

CompletedNCT01568385

A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Takeda · Industry
Sex
All
Age
20 Years
Healthy volunteers

Summary

The purpose of this study is to study the safety and efficacy of TAK-438, once daily (QD), in participants with a history of gastric or duodenal ulcer requiring long-term NSAID therapy will be investigated.

Conditions

Interventions

TypeNameDescription
DRUGTAK-438

Timeline

Start date
2012-04-01
Primary completion
2013-09-01
Completion
2013-09-01
First posted
2012-04-02
Last updated
2014-02-10

Locations

18 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT01568385. Inclusion in this directory is not an endorsement.

A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Ster (NCT01568385) · Clinical Trials Directory